CytoDyn acquires Pro 140 from Progenics Pharmaceuticals - MarketLine Financial Deals

CytoDyn acquires Pro 140 from Progenics Pharmaceuticals

CytoDyn acquires Pro 140 from Progenics Pharmaceuticals - MarketLine Financial Deals
CytoDyn acquires Pro 140 from Progenics Pharmaceuticals
Published Oct 17, 2012
3 pages — Published Oct 17, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

CytoDyn, Inc., a biotechnology research company, has acquired Pro 140 from Progenics Pharmaceuticals, Inc.

  
Source:
Document ID
MA126407_121025
Country
Ticker
CYDY=US
Ticker
PGNX=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "CytoDyn acquires Pro 140 from Progenics Pharmaceuticals" Oct 17, 2012. Alacra Store. Dec 06, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/CytoDyn-acquires-Pro-140-from-Progenics-Pharmaceuticals-2052-88364>
  
APA:
MarketLine Financial Deals. (2012). CytoDyn acquires Pro 140 from Progenics Pharmaceuticals Oct 17, 2012. New York, NY: Alacra Store. Retrieved Dec 06, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/CytoDyn-acquires-Pro-140-from-Progenics-Pharmaceuticals-2052-88364>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.